Evidence map›Paper›PMID 38207170›Full record

ArticleAdvanced healthcare materials2024

Local and Sustained Baricitinib Delivery to the Skin through Injectable Hydrogels Containing Reversible Thioimidate Adducts.

Leo L Wang, Spencer Tuohy, Karen L Xu, Arben Nace, Ruifeng Yang, Ying Zheng, Jason A Burdick, George Cotsarelis

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Leo L WangDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, 1053 Biomedical Research Building, 421 Curie Blvd, Philadelphia, PA, 19104, USA.ORCID 0000-0002-1424-0481
Spencer TuohyDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, 1053 Biomedical Research Building, 421 Curie Blvd, Philadelphia, PA, 19104, USA.
Karen L XuDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, 220 South 33rd Street, 107 Towne Building, Philadelphia, PA, 19104-6391, USA.
Arben NaceDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, 1053 Biomedical Research Building, 421 Curie Blvd, Philadelphia, PA, 19104, USA.
Ruifeng YangDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, 1053 Biomedical Research Building, 421 Curie Blvd, Philadelphia, PA, 19104, USA.
Ying ZhengDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, 1053 Biomedical Research Building, 421 Curie Blvd, Philadelphia, PA, 19104, USA.
Jason A BurdickDepartment of Bioengineering, School of Engineering and Applied Science, University of Pennsylvania, 220 South 33rd Street, 107 Towne Building, Philadelphia, PA, 19104-6391, USA.
George CotsarelisDepartment of Dermatology, Perelman School of Medicine, University of Pennsylvania, 1053 Biomedical Research Building, 421 Curie Blvd, Philadelphia, PA, 19104, USA.ORCID 0000-0003-3534-9408

Funding

Penn Dermatology Research Training ProgramT32AR007465 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice, David Joel Margolis · 1986 to 2026
$9.0M
Study Design and Data AnalysisP30AR069589 · NIAMS · UNIVERSITY OF PENNSYLVANIA · PI Elizabeth Anne Grice · 2016 to 2026
$8.6M
NIAMS NIH HHS P30 AR069589NIAMS NIH HHS P30-AR069589NIAMS NIH HHS T32 AR007465
6 · The paper itself

Abstract

Janus kinase (JAK) inhibitors are approved for many dermatologic disorders, but their use is limited by systemic toxicities including serious cardiovascular events and malignancy. To overcome these limitations, injectable hydrogels are engineered for the local and sustained delivery of baricitinib, a representative JAK inhibitor. Hydrogels are formed via disulfide crosslinking of thiolated hyaluronic acid macromers. Dynamic thioimidate bonds are introduced between the thiolated hyaluronic acid and nitrile-containing baricitinib for drug tethering, which is confirmed with

Indexed as

AzetidinesHydrogelsPurinesPyrazolesSkinSulfonamidesAnimalsFemaleHumansImiquimodJanus Kinase InhibitorsMicePsoriasisAzetidinesbaricitinibHydrogelsImiquimodJanus Kinase InhibitorsPurinesPyrazolesSulfonamidesdermatologyhydrogelJAK‐STATpsoriasisthioimidate

Identifiers

PMID38207170
PMCPMC11076163

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.